₹924.25
+4.51%NSE close, 16 Nov 2026
+9.83%
Orchid Pharma is a small cap company, listed on NSE under the symbol ORCHPHARMA. At ₹924.25 a share, the market values the whole company at ₹5,535 crore.
In FY26, it reported sales of ₹1,233 crore and a net profit of ₹10 crore, an operating margin of 2.7%. Over the last three years, sales grew 22.8% a year and net profit fell 40.1% a year.
The market values the company at 122.9 times its profit over the last twelve months and 3.39 times its book value; its return on equity is 2.8% and its borrowings are 0.33 times its equity.
Promoters hold 74.45% of the shares. Foreign institutions hold 0.93%, and domestic institutions, mutual funds among them, 17.44%.
Over the past year the share price has risen 11.4%, and it is 19.2% below its 52-week high.
₹ crore. Consolidated figures.
Board comments on fine levied by the Exchange
The financial results for the period ended September 30, 2026.
Monitoring Agency Report for Quarter-II ended on September 30,2026
Schedule of meet
Announcement under Regulation 30 regarding the licensing and supply agreement with Laboratorio Libra S.A.("Libra"}
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 221 | 217 | 244 | 223 | 217 | 237 | 173 | 194 | 207 | 368 | 304 | 341 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 185 | 188 | 212 | 192 | 191 | 210 | 159 | 195 | 206 | 338 | 290 | 317 |
| Operating profit | 35.4 | 28.9 | 32.5 | 30.3 | 26.4 | 28.0 | 14.2 | −1.5 | 1.6 | 30.2 | 14.0 | 24.1 |
| Operating margin | 16.0% | 13.3% | 13.3% | 13.6% | 12.1% | 11.8% | 8.2% | -0.8% | 0.8% | 8.2% | 4.6% | 7.1% |
| Other income | 7.6 | 13.4 | 7.6 | 7.5 | 8.5 | 3.9 | 11.5 | 10.8 | 5.6 | 7.8 | 1.8 | 17.8 |
| Interest | 3.5 | 3.5 | 3.5 | 3.3 | 3.8 | 3.9 | 3.3 | 3.7 | 3.2 | 2.0 | 2.2 | 3.6 |
| Depreciation | 9.3 | 8.4 | 8.4 | 8.6 | 8.6 | 8.9 | 8.7 | 8.9 | 9.0 | 10.9 | 11.0 | 11.4 |
| Profit before tax | 30.2 | 30.4 | 28.1 | 25.9 | 22.5 | 19.1 | 13.7 | −3.3 | −12.2 | 24.9 | 2.7 | 26.8 |
| Tax | 0 | −3.1 | −0.2 | 0 | 0 | −0.0 | 0 | 0 | 0 | 0 | 0.1 | −0.0 |
| Net profit | 29.4 | 33.0 | 29.4 | 27.2 | 20.8 | 22.3 | 14.9 | −5.7 | −12.6 | 25.8 | 3.2 | 28.6 |
| EPS (₹) | 6.18 | 6.81 | 5.79 | 5.37 | 4.10 | 4.40 | 2.94 | -1.13 | -2.49 | 4.31 | 0.54 | 4.77 |
₹ crore, financial years to March.
| Line | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Sales | 450 | 560 | 666 | 819 | 922 | 1,233 |
| Expenses | 400 | 510 | 582 | 710 | 805 | 1,199 |
| Operating profit | 49.8 | 49.6 | 83.6 | 110 | 117 | 33.6 |
| Operating margin | 11.1% | 8.9% | 12.6% | 13.4% | 12.7% | 2.7% |
| Other income | 15.2 | 9.0 | 19.4 | 31.2 | 27.5 | 36.4 |
| Interest | 51.3 | 32.0 | 54.6 | 16.4 | 14.5 | 9.0 |
| Depreciation | 109 | 87.0 | 32.5 | 33.2 | 34.6 | 43.3 |
| Profit before tax | −95.3 | −60.4 | 55.3 | 91.4 | 95.6 | 10.4 |
| Tax | 0 | 0 | 0 | −3.1 | −0.2 | −0.2 |
| Net profit | −117 | −2.0 | 46.3 | 91.6 | 99.7 | 10.0 |
| EPS (₹) | -28.55 | -0.48 | 7.67 | 19.14 | 19.65 | 1.66 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 689 | 1,169 | 1,267 | 1,564 | 1,632 |
| Borrowings | 331 | 134 | 174 | 301 | 544 |
| Total liabilities | 537 | 384 | 421 | 694 | 1,020 |
| Fixed assets | 573 | 619 | 632 | 687 | 722 |
| Investments | 44.4 | 45.8 | 49.7 | 67.0 | 54.9 |
| Cash and equivalents | 22.6 | 3.6 | 21.1 | 7.1 | 46.6 |
| Total assets | 1,225 | 1,554 | 1,688 | 2,258 | 2,652 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 89.0 | 19.2 | 126 | 118 |
| From investing | 116 | −26.9 | −277 | −315 |
| From financing | −217 | 25.2 | 137 | 236 |
| Spent on fixed assets | −14.4 | −150 | −390 | −395 |
| Free cash flow | 74.6 | −131 | −264 | −278 |
Margins, returns, debt, tax and cash.
| Line | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Net margin | -25.9% | -0.3% | 7.0% | 11.2% | 10.8% | 0.8% |
| Operating margin | 11.1% | 8.9% | 12.6% | 13.4% | 12.7% | 2.7% |
| Return on equity | – | – | 6.7% | 7.8% | 7.9% | 0.6% |
| Return on capital employed | – | – | 10.8% | 8.3% | 7.6% | 1.0% |
| Return on assets | – | – | 3.8% | 5.9% | 5.9% | 0.4% |
| Debt to equity | – | – | 0.48 | 0.11 | 0.14 | 0.19 |
| Interest coverage | -0.90 | -0.90 | 2.00 | 6.60 | 7.60 | 2.20 |
| Debt to assets | – | – | 0.27 | 0.09 | 0.10 | 0.13 |
| Current ratio | – | – | 1.35 | 3.04 | 2.83 | 1.89 |
| Quick ratio | – | – | 0.73 | 2.03 | 1.68 | 1.13 |
| Cash ratio | – | – | 0.06 | 0.01 | 0.07 | 0.01 |
| Asset turnover | – | – | 0.54 | 0.53 | 0.55 | 0.55 |
| Fixed asset turnover | – | – | 1.16 | 1.32 | 1.46 | 1.80 |
| Inventory turnover | – | – | – | 1.80 | 1.70 | 2.30 |
| Receivables turnover | – | – | 3.10 | 4.20 | 3.80 | 3.20 |
| Gross margin | – | – | – | 40.9% | 41.0% | 31.5% |
| Cash from operations to profit | – | – | – | – | 19.0% | 1,261.0% |
| Effective tax rate | – | – | 0.0% | – | – | – |
Outcome of Board Meeting held on October 20, 2026.
A copy Srutinizers report of 33rd Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of the 33rd Annual General Meeting held on September 29, 2026
Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation
Intimation under Regulation 30 of SEBI ( Listing obligation and Disclosure Requirement) Regulations, 2015
Investor Roadshow Scheduled to be held in Mumbai
Business Responsibility and Sustainability Report for FY 2025-26